Stock Analysts

Jacobs (JEC) Wins EPC Deal from SPCC, Boosts Organic Growth

Jacobs Engineering Group Inc. JEC boosted its organic growth path on the back of a new engineering, procurement and construction (EPC) deal secured from the Southern Peru Copper Corporation (“SPCC”). Shares of this Zacks Rank #3 (Hold) stock yielded a return of 1.4%, as against the loss of 0.2% incurred by the industry in three months’ time […]

Stock Analysts

CoreSite Picked by Faction for Multi-Cloud Service Expansion

CoreSite Realty Corporation COR has been selected by enterprise-class private cloud and backup infrastructure provider — Faction — as its partner for rolling out multi-cloud storage and network solutions, and expand its VMware private-cloud services. This partnership with CoreSite has taken place in both the Northern Virginia and Silicon Valley markets. The company’s scalable data center platform, high-performance interconnection solutions and proximity to the key public cloud providers are the reasons for being selected by Faction. […]

Stock Analysts

Luminex Partners Sutter Health to Boost Molecular Testing

Following a strong revenue performance in the second quarter, Luminex Corporation LMNX announced plans to collaborate with Sutter Health to bolster its molecular diagnostic testing portfolio. The collaboration is expected to enhance the company’s patient care techniques, especially in cases of Cystic Fibrosis, gastrointestinal illness and respiratory tract infections. Meanwhile, shares of Luminex have inched 0.3% up following the news release […]

Stock Analysts

Hain Celestial (HAIN) Q4 Earnings & Sales Beat Estimates

The Hain Celestial Group, Inc. HAIN reported better-than-expected financial numbers in fourth-quarter fiscal 2017 after missing the Zacks Consensus Estimate in the previous quarter. The company reported adjusted earnings per share of 43 cents, flat year over year but ahead of the Zacks Consensus Estimate of 40 cents […]

Stock Analysts

Analog Devices (ADI) Beats Q3 Earnings and Revenue Estimates

Analog Devices Inc. ADI reported fiscal third-quarter 2017 adjusted earnings of $1.26 per share, which beat the Zacks Consensus Estimate of $1.15. The better-than-expected results were driven by strength across all the markets – industrial, automotive, consumer and communications, and positive contributions from Linear Technology acquisition. […]

Stock Analysts

Will GoM Oil Refiners, Drillers Survive the Harvey Mayhem?

As Hurricane Harvey tore through the Texas Gulf Coast–the devastating storm just made landfall again, this time in Louisiana–workers in the U.S. oil industry have struggled to evacuate production facilities and shut down refineries. This, in turn, triggered the biggest disruption in nationwide energy supplies in years, driving gasoline prices higher at the pumps. […]

Stock Analysts

Western Digital Continues Acquisition Spree with Tegile Buy

Western Digital Corporation WDC has been on an acquisition spree lately. Post the company’s buyout of Upthere, an app-based cloud-storage startup, yesterday, this hard disk drive (HDD) producer is set for another strategic acquisition. Western Digital signed an agreement to acquire Tegile Systems (“Tegile”) for an undisclosed amount […]

Stock Analysts

Here’s Why TreeHouse Stock Lost More Than 20% Since Earnings

TreeHouse Foods, Inc. THS has been displaying disappointing performance lately, owing to unfavorable market conditions, evolving consumer buying pattern and operating inefficiencies. These factors had a negative impact upon the company’s recently reported second-quarter 2017 results on Aug 3, post which share price have declined 21.2% […]

Stock Analysts

AstraZeneca and Takeda Ink Deal to Develop Parkinson’s Drug

AstraZeneca PLC AZN and Takeda Pharmaceutical Company Limited, a Japanese pharma company, have entered into an agreement to jointly develop and commercialize preclinical candidate MEDI1341. In fact, MEDI1341 is an alpha-synuclein antibody being developed for the potential treatment of Parkinson’s disease (PD). The candidate is due to enter phase I studies later this year […]

Stock Analysts

Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule

ImmunoGen Inc. IMGN announced a strategic collaboration and option agreement with Jazz Pharmaceuticals PLC JAZZ for the development and commercialization of two early-stage, hematology-related antibody-drug conjugate (ADC) programs, and also another l program which will be designated during the term of the agreement. The programs include IMGN779 – a CD33-targeting ADC and which is in phase I study for the treatment of acute myeloid leukemia (AML) and IMGN632 also being evaluated in a preclinical study for treating hematological malignancies including AML […]